Medpace Holdings, Inc. (NASDAQ:MEDP) is set to announce second quarter earning results on Monday 27th July 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, MEDP to report 2Q20 income of $ 0.41 per share.
For the full year, analysts anticipate top line of $ 828.78 million, while looking forward to income of $ 2.36 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 975.00 million ~ $ 1,005.00 million, where as bottomline are predicted in a range of $ 3.24 ~ $ 3.34 per share
Click Here For More Historical Outlooks Of Medpace Holdings, Inc.
Previous Quarter Performance
Medpace Holdings, Inc. communicated income for the first quarter of $ 0.76 per share, from the revenue of $ 230.88 million. The quarterly earnings surged 18.75 percent while revenues developed 15.01 percent compared with the same quarter last year.
Street analysts expected Medpace Holdings, Inc. to report income of $ 0.75 per share on revenue of $ 226.32 million for the first quarter. The bottom line results beat street analysts by $ 0.01 or 1.33 percent, at the same time, top line results outshined analysts by $ 4.56 million or 2.01 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Medpace Holdings, Inc.
Stock Performance
According to the previous trading day, closing price of MEDP was $ 105.81, representing a 80.19 % increase from the 52 week low of $ 58.72 and a 7.28 % decrease over the 52 week high of $ 114.12.
The company has a market capital of $ 3.74 billion and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”MEDP” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 8th June 2020, upgraded by Robert W. Baird to Neutral from Underperform rating.
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
